Is GWPH a buy or sell?
The VGM score is based on the trading styles of Growth, VAlue, and Momentum....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy25.08%2Buy18.56%3Hold10.15%4Sell5.79%2 more rows
Who is buying GWPH?
On Friday, shareholders of GW Pharmaceuticals (GWPH) approved its acquisition by a subsidiary of Jazz Pharmaceuticals (JAZZ 2.58%), both companies announced in a joint press release.
What happen to GWPH?
Jazz Pharmaceuticals (NASDAQ:JAZZ) has officially closed its $7.2B acquisition of GW Pharmaceuticals plc (NASDAQ:GWPH). GW shareholders gave the thumbs up to the deal last month. With the acquisition, Jazz gains access to GW's cannabinoid portfolio, including Epidiolex, which raked in $510.5M in sales in 2020.
Did GWPH get bought out?
DUBLIN , May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) ("GW"), a leader in the science, development and commercialization of cannabinoid-based prescription medicines.
Which stock wins in a battle between these two cannabis-focused biotechs?
There really aren't very many biotechs that are primarily focused on developing cannabinoid drugs -- at least not many that trade publicly. GW Pharmaceutical s ( GWPH ) and Insys Therapeutics ( INSY ) rank at the top of the list in terms of market cap.
The case for Insys Therapeutics
Quite honestly, Insys Therapeutics has pretty much been a "bad news biotech" for much of the last couple of years. The company faced plunging sales for its main product, opioid drug Subsys. It was under investigation by the U.S. Department of Justice (DOJ) for alleged sales and marketing practices for Subsys.
The case for GW Pharmaceuticals
In comparison to Insys, any problems that GW Pharmaceuticals might have look insignificant. The biotech won FDA approval earlier this year for cannabidiol (CBD) drug Epidiolex as a treatment for Dravet syndrome and Lennox-Gastaut syndrome (LGS), two rare forms of epilepsy.
Better buy
In my view, GW Pharmaceuticals gets the nod as the better pick right now. Insys still has too many questions about Subsys and the potential for Syndros. Meanwhile, GW claims an approved drug with significant commercial potential that that should be launched very soon.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
What is GW Pharmaceuticals?
Biopharmaceutical company GW Pharmaceuticals PLC-ADR ( GWPH) is one of the pioneers in the arena of prescription-level, cannabis-based therapies. Its Sativex is a cannabinoid drug aimed at spasticity due to multiple sclerosis patients. The drug is also being developed as a therapy for pain, and cancer-related pain in particular.
Is Insys a pure play company?
Insys Therapeutics Inc ( INSY) isn’t a pure-play marijuana stock, but it does have one cannabinoid-based drug in its pipeline … oral dronabinol, which is a close cousin of nausea/anorexia therapy Marinol. Marinol generates more than $100 million in annual revenue, but an easier-to-use formulation of the treatment could prove bullish for INSY stock.